Episode Summary
Executive Summary: Ethan Weiss and Josh Lehrer discuss Marea Biosciences’ first-in-class monoclonal antibody against AngPTL4, a target validated by human genetics and now backed by phase 1/2 data showing >50% reductions in triglycerides and remnant cholesterol without mouse-like safety signals. They explain how the company moved from adipose biology to cardiovascular risk reduction, and why a larger phase 2b trial in high-risk patients could position AngPTL4 inhibition as a novel precision medicine for residual cardiovascular risk.
Main Topics: Origin of Marea and the AngPTL4 hypothesis (Priority: 5/5): The founders describe how an idea about fat function, lipodystrophy, and human genetics evolved into targeting AngPTL4 as a way to improve cardiometabolic disease risk independently of BMI. Why fat distribution matters more than weight alone (Priority: 5/5): They argue that fat is an active organ and that where fat is stored—especially visceral vs gluteofemoral—helps explain insulin resistance, diabetes, and coronary disease beyond total body weight. Mouse data vs human genetics in target validation (Priority: 5/5): The conversation explains why early mouse knockout findings made some groups wary, but why large human genetics datasets, including protective loss-of-function variants, made the target compelling for Marea. Clinical proof-of-concept for AngPTL4 inhibition (Priority: 5/5): They review the licensed Novartis asset and Marea’s own placebo-controlled trial showing substantial biomarker improvements and no concerning imaging or tolerability signals. Remnant cholesterol as a causal risk marker (Priority: 4/5): Josh explains what remnant cholesterol is, why it matters biologically, and why lowering it may reduce cardiovascular events more directly than triglycerides alone. Phase 2b strategy and patient selection (Priority: 5/5): Marea is moving toward a larger, longer, randomized study in higher-risk patients with diabetes and established cardiovascular disease to test whether the biomarker improvements translate into meaningful residual-risk reduction. Future of precision cardiovascular medicine (Priority: 4/5): They envision a treatment paradigm where statins, GLP-1s, Lp(a) drugs, and AngPTL4 inhibition are chosen based on the specific residual-risk biology of each patient.
Key Arguments: The company began with a broad mandate to address a major disease area without competing directly in crowded LDL-lowering or obesity categories. Human genetics pointed to AngPTL4 as a rare but attractive knockout target: people with loss-of-function variants appear healthier, have lower triglycerides and remnant cholesterol, and lower risk of coronary disease and type 2 diabetes. The mouse safety signal likely reflects a species-specific developmental issue rather than a showstopper in humans, since human carriers appear healthy. Remnant cholesterol is more mechanistically relevant than triglycerides alone because it reflects cholesterol carried on triglyceride-rich particles that contribute to atherosclerosis. Marea’s drug has now shown biomarker efficacy and tolerability in humans, supporting advancement to a larger phase 2b study. The most promising path is not rare-disease-only development but a high-risk secondary-prevention strategy targeting residual cardiovascular risk. The drug may complement, not replace, statins and GLP-1s because there is limited overlap and many patients will still have elevated remnant cholesterol despite existing therapies.
Data Points: Capital raised: $190 million - Marea Biosciences funding across a couple of venture rounds Human genetic variant frequency: ~2% allele frequency - Estimated common loss-of-function frequency for AngPTL4 U.S. carriers: ~10 million - Approximate number of people in the United States carrying the variant Triglyceride/remnant cholesterol reduction: More than 50% - Recent clinical trial results published in The Lancet Higher-response subgroup: ~60% reduction - Patients starting with higher baseline levels showed larger biomarker drops Total treated patients: Over 100 - Combined Novartis and Marea clinical experience with the antibody Novartis phase 1 study size: ~55 people - Single-dose first-in-human study run by Novartis Marea phase 2a study size: ~55 people - Multiple-dose clinical experience run by Marea Marea treatment duration: 12 weeks dosing + 12 weeks follow-up - Recent randomized placebo-controlled study design Planned phase 2b size: About 200 patients - Next larger study in higher-risk patients Phase 2b dosing duration: 6 months - Longer treatment period than phase 2a Earlier dosing interval: Every 2 weeks - Phase 2a antibody dosing schedule Expected future dosing interval: Every 2 or 4 weeks - Planned phase 3 regimen under modeling Projected coronary disease deaths by 2050: Up 90% globally - Cited as rationale for large unmet need Lp(a) prevalence in secondary prevention discussion: Roughly 5% - Used as an example of precision targeting in heart disease
Pivotal Quotes: "What we're doing actually... is that this drug reduces heart attacks." — Josh Lehrer: Explaining the moment the company shifted from a rare-disease-style plan to a broader cardiovascular prevention strategy "The problem is that people have this bad habit of trusting mice more than humans." — Josh Lehrer: Describing why early mouse knockout safety concerns delayed wider development of AngPTL4 "This is the target. It's really an incredible target." — Luke Timmerman / discussion framing: Summarizing the enthusiasm around AngPTL4 after human genetic and clinical validation
Implications: If phase 2b confirms benefit, AngPTL4 inhibition could become a precision cardiovascular drug for patients with residual risk despite standard therapy, expanding treatment beyond LDL lowering and obesity management.
About The Long Run with Luke Timmerman
"The Long Run" Antarctic explorer Ernest Shackle…